Trial: 201811110

A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma

Phase

I/II

Principal Investigator

Mehta-Shah, Neha

Disease Site

Hodgkin’s Lymphoma

Learn more about this study at: clinicaltrials.gov